Reneuron Group (RENE)

 

Latest News

Appointment of joint broker

RNS Number: 9482L ReNeuron Group plc 25 July 2017 AIM: RENE 25 July 2017 ReNeuron Group plc Appointment of joint broker ReNeuron Group plc (the "Company") (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce the appointment of Nplus1 Singer Advisory LLP as joint broker to the Company with immedia...

Board change

RNS Number: 4399L ReNeuron Group plc 19 July 2017 AIM: RENE 19 July 2017 ReNeuron Group plc Board change ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that Dr Paul Harper , a non-executive director of the business since the Company's flotation on AIM in 200...

ReNeuron widens FY pretax loss

ReNeuron has widened its FY pretax loss to 18.2m, from a loss of 12.8m. This followed its operating loss of 19.9m, from 13.7m...

Preliminary Results

RNS Number: 5135J ReNeuron Group plc 29 June 2017 29 June 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Preliminary Results for the Year Ended 31 March 2017 ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31...

All News

DateHeadlineSource
25-07-17Appointment of joint brokerRNS
19-07-17Board changeRNS
29-06-17ReNeuron widens FY pretax lossStockMarketWire
29-06-17Preliminary ResultsRNS
19-06-17ReNeuron says FDA okays cryopreserved hRPC formulationStockMarketWire
19-06-17FDA approves cryopreserved hRPC formulationRNS
08-06-17Notification of Preliminary ResultsRNS
05-06-17ReNeuron gets favourable feedback from US FDAStockMarketWire
05-06-17Positive FDA feedback on proposed Phase III studyRNS
18-05-17ReNeuron presents positive exosome dataStockMarketWire
18-05-17Presents positive exosome data at major conferenceRNS
11-05-17ReNeuron awarded £1.8m grant from Innovate UKStockMarketWire
11-05-17Awarded major UK cell therapy manufacturing grantRNS
05-05-17Presents new exosome data at major conferenceRNS
21-04-17ReNeuron updates on ophthalmology programmesStockMarketWire
21-04-17ReNeuron updates on clinical strategy in stroke disabilityStockMarketWire
21-04-17Update on clinical strategy in stroke disabilityRNS
21-04-17Update on progress in ophthalmology programmesRNS
01-03-17Block Listing Review and Total Voting RightsRNS
15-02-17ReNeuron featured in BBC documentaryRNS
07-02-17Director Deals - ReNeuron Group PLC (RENE)StockMarketWire
07-02-17Director Share PurchaseRNS
01-02-17ReNeuron Group to present at the Shares Spotlight Evening in Edinburgh on 15 February 2017StockMarketWire
14-12-16Director Share PurchaseRNS
05-12-16ReNeuron widens H1 pretax lossStockMarketWire
05-12-16ReNeuron reports positive results in Phase II Stroke TrialStockMarketWire
05-12-16Reports Positive Results in Phase II Stroke TrialRNS
05-12-16Interim ResultsRNS
14-11-16Notification of Interim ResultsRNS
14-10-16ReNeuron Group Plc to present at the Shares Investor Evening in London on 27th October 2016StockMarketWire
05-10-16Notification of Major Interest in SharesRNS
22-09-16Block Listing Review and Total Voting RightsRNS
06-09-16ReNeuron passes AGM resolutionsStockMarketWire
06-09-16Result of AGMRNS
06-09-16AGM Trading UpdateRNS
05-08-16Posting of Annual Report and Notice of AGMRNS
04-08-16Stroke clinical data published in The LancetRNS
22-07-16Publication of positive pre-clinical retinal dataRNS
20-07-16Directors' Interest in Shares and Share OptionsRNS
07-07-16Preliminary ResultsRNS

RSS feeds

  • Editorial news feed for LSE:RENE Editorial
  • Regulatory news feed for LSE:RENE Regulatory